Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06782555RecruitingPhase 1/Phase 2
Study of experimental drug combo for advanced cancers
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Houston, TexasAges 18 years+ - NCT06841211Recruiting
Optimizing prostate biopsy for multiple MRI lesions
This study aims to find the best way to take tissue samples (biopsies) from the prostate when MRI shows more than one suspicious spot. It will help doctors know exactly where to biopsy to reduce false negatives and avoid missing cancer.
Beijing, Beijing MunicipalityAges 18–85 - NCT06591819RecruitingPhase 2
Shorter pelvic radiation with HDR boost for prostate cancer
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05974774RecruitingPhase 3
Intermittent hormone therapy for metastatic prostate cancer with low PSA
This trial studies whether taking hormone therapy in breaks (instead of continuously) can work for people with metastatic prostate cancer whose PSA is very low after prior treatment with hormone-deprivation plus an AR pathway inhibitor. It may help reduce time on treatment while still keeping cancer controlled.
CopenhagenAges 18–100 - NCT06280781Recruiting
Long-term active surveillance for prostate cancer
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
Ascot, BerkshireAges 18 years+ - NCT06177093Recruiting
Higher dose prostate radiation with MRI guidance
This study tests a higher dose of radiation for prostate cancer using an MRI-guided machine (MR-Linac). It aims to see if a more targeted dose can be safely given to the tumor while protecting healthy tissue.
Toronto, OntarioAges 18 years+ - NCT07126548Recruiting
Virtual reality help for Black men with new prostate cancer
This study tests if a virtual reality tool can help newly diagnosed Black men understand their prostate cancer better and feel more supported. You would use the VR tool to learn about your diagnosis and treatment options.
Jacksonville, FloridaAges Any age - NCT06825091RecruitingPhase 3
Comparing new SBRT to standard radiation for prostate cancer
This trial compares a newer, more precise type of radiation (adaptive SBRT) with standard image-guided radiation for prostate cancer. It aims to see if the newer approach is better at targeting the tumor while reducing side effects.
Toronto, OntarioAges 18 years+ - NCT06542757Recruiting
Focused radiation to main prostate tumor using MRI guidance
This trial tests a stronger, more focused radiation dose to the main tumor inside the prostate using MRI guidance. It aims to improve control of intermediate-risk prostate cancer while possibly reducing side effects.
New York, New YorkAges 18 years+ - NCT04472338Recruiting
Prostate cancer screening for people with higher genetic risk
This study looks at prostate cancer screening for people who may be at higher risk because of a specific inherited (genetic) change. It may help your care team find the best screening approach to catch aggressive prostate cancer earlier.
Duarte, CaliforniaAges 40 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT06472817Enrolling by invitation
Social factors affecting prostate cancer care in African and Caribbean men
This study looks at how social and cultural factors affect prostate cancer care and long-term health in Black immigrant men from Sub-Saharan Africa and the Caribbean. Your experiences can help improve cancer care for others like you.
Atlanta, GeorgiaAges 18 years+ - NCT03861676RecruitingEarly Phase 1
PET-guided targeted radiation for early prostate cancer
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
Baltimore, MarylandAges 18–100 - NCT07184970Recruiting
Detecting prostate cancer return after HIFU with advanced scans
This trial uses a special PET/MRI scan to check if prostate cancer has come back after high-intensity focused ultrasound (HIFU) treatment. It aims to find any remaining cancer early so doctors can plan next steps.
New York, New YorkAges 40–95 - NCT07142551RecruitingPhase 2
Testosterone priming with darolutamide for metastatic prostate cancer
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Baltimore, MarylandAges 18 years+ - NCT06126731RecruitingPhase 1/Phase 2
Antibiotics plus enzalutamide for advanced prostate cancer
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
BellinzonaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06066437RecruitingPhase 1/Phase 2
Lutetium before prostate surgery for high-risk cancer
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Houston, TexasAges 18 years+ - NCT07550517RecruitingPhase 2
Radiation plus experimental nuclear medicine for high-risk prostate cancer
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
Baltimore, MarylandAges 18 years+ - NCT06875258RecruitingPhase 4
Penile rehab after nerve-sparing prostate surgery
This trial tests a penile rehabilitation program for men who have nerve-sparing prostate cancer surgery. It aims to help improve erections and sexual function after the procedure.
Nijmegen, GelderlandAges 18–70 - NCT07197723Recruiting
Study of decision making about prostate cancer risk
This study looks at how men with a BRCA1/2 gene change make decisions about their health and prostate cancer risk. Participants will fill out surveys to help researchers understand these choices.
New York, New YorkAges 45–70 - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+ - NCT05038332RecruitingPhase 2
Testing two types of radiation after prostate surgery
This Phase 2 study compares two schedules of radiation treatment after prostate surgery in men whose PSA starts rising again. It aims to see which radiation approach works well while tracking quality of life and safety.
Ann Arbor, MichiganAges 18 years+ - NCT07476001RecruitingPhase 2
High-dose testosterone and PSMA-targeted radiation for prostate cancer
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Tampa, FloridaAges 18 years+
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.